Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 3 of the 15 sources its claims cite were checked for support.

Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis

Open access
Mayo-Wilson, Evan, Dias, Sofia, Mavranezouli, Ifigeneia, Kew, Kayleigh, Clark, David M, Ades, A E, Pilling, Stephen · 2014 · The Lancet Psychiatry

Abstract

BACKGROUND: Social anxiety disorder-a chronic and naturally unremitting disease that causes substantial impairment-can be treated with pharmacological, psychological, and self-help interventions. We aimed to compare these interventions and to identify which are most effective for the acute treatment of social anxiety disorder in adults. METHODS: We did a systematic review and network meta-analysis of interventions for adults with social anxiety disorder, identified from published and unpublished sources between 1988 and Sept 13, 2013. We analysed interventions by class and individually. Outcomes were validated measures of social anxiety, reported as standardised mean differences (SMDs) compared with a waitlist reference. This study is registered with PROSPERO, number CRD42012003146. FINDINGS: We included 101 trials (13 164 participants) of 41 interventions or control conditions (17 classes) in the analyses. Classes of pharmacological interventions that had greater effects on outcomes compared with waitlist were monoamine oxidase inhibitors (SMD -1·01, 95% credible interval [CrI] -1·56 to -0·45), benzodiazepines (-0·96, -1·56 to -0·36), selective serotonin-reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors (SSRIs and SNRIs; -0·91, -1·23 to -0·60), and anticonvulsants (-0·81, -1·36 to -0·28). Compared with waitlist, efficacious classes of psychological interventions were individual cognitive-behavioural therapy (CBT; SMD -1·19, 95% CrI -1·56 to -0·81), group CBT (-0·92, -1·33 to -0·51), exposure and social skills (-0·86, -1·42 to -0·29), self-help with support (-0·86, -1·36 to -0·36), self-help without support (-0·75, -1·25 to -0·26), and psychodynamic psychotherapy (-0·62, -0·93 to -0·31). Individual CBT compared with psychological placebo (SMD -0·56, 95% CrI -1·00 to -0·11), and SSRIs and SNRIs compared with pill placebo (-0·44, -0·67 to -0·22) were the only classes of interventions that had greater effects on outcomes than appropriate placebo. Individual CBT also had a greater effect than psychodynamic psychotherapy (SMD -0·56, 95% CrI -1·03 to -0·11) and interpersonal psychotherapy, mindfulness, and supportive therapy (-0·82, -1·41 to -0·24). INTERPRETATION: Individual CBT (which other studies have shown to have a lower risk of side-effects than pharmacotherapy) is associated with large effect sizes. Thus, it should be regarded as the best intervention for the initial treatment of social anxiety disorder. For individuals who decline psychological intervention, SSRIs show the most consistent evidence of benefit. FUNDING: National Institute for Health and Care Excellence.

Overview

CoChat Summary

## TL;DR

This systematic review and network meta-analysis found that both psychological and pharmacological treatments improve acute outcomes for adult social anxiety disorder, with individual CBT showing the largest and most consistent effects. The authors conclude that individual CBT should be the initial treatment of choice, while SSRIs are the most consistent drug option for people who decline psychological treatment.

## Key findings

  • The review included 101 trials with 13,164 participants and 41 interventions or control conditions grouped into 17 classes.
  • Compared with waitlist, the largest class-level effects were for individual CBT (SMD −1.19, 95% CrI −1.56 to −0.81), group CBT (−0.92, −1.33 to −0.51), and pharmacological classes including MAOIs (−1.01, −1.56 to −0.45), benzodiazepines (−0.96, −1.56 to −0.36), and SSRIs/SNRIs (−0.91, −1.23 to −0.60).
  • Against appropriate placebo, only individual CBT versus psychological placebo (SMD −0.56, 95% CrI −1.00 to −0.11) and SSRIs/SNRIs versus pill placebo (−0.44, −0.67 to −0.22) showed clear benefit.
  • Individual CBT outperformed several other psychological interventions, including psychodynamic psychotherapy (SMD −0.56, 95% CrI −1.03 to −0.11) and interpersonal psychotherapy, mindfulness, and supportive therapy (−0.82, −1.41 to −0.24).

## Methods

  • Systematic review and Bayesian random-effects network meta-analysis of adult randomized clinical trials for social anxiety disorder, using waitlist as the main reference condition.
  • Searched published and unpublished sources from 1988 to Sept 13, 2013, with no language limits; included adults aged at least 18 years who met diagnostic criteria for social anxiety disorder.
  • Outcomes were validated measures of social anxiety, analyzed as standardised mean differences (SMDs); the paper also estimated recovery where reported and compared interventions both by class and individually.

## Limitations

  • The paper states that only a few studies of moderate size were available for several interventions, and some had been tested by only one or two research groups.
  • Control conditions were heterogeneous and rarely described in detail, and the authors note that better reporting of what was intended and received is needed.
  • The study included only end-of-treatment outcomes; the authors say they could not assess whether effects persist long term because most trials stopped at the end of treatment.
  • Evident from the text: there was substantial risk of bias/reporting bias in the evidence base, including many unregistered trials, incomplete outcome data in some trials, and only 28 trials at low risk of bias for all non-masking domains.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s2215-0366(14)70329-3

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 PRISMA flowchart PRISMA=Preferred Reporting Items for Systematic reviews and Meta-Analyses.
Figure 1 PRISMA flowchart PRISMA=Preferred Reporting Items for Systematic reviews and Meta-Analyses.CC BY · PubMed Central
Figure 2 Network diagram representing direct comparisons among classes The width of lines represents the number of trials in which each direct comparison is made. The size of each circle represents the number of people who received each treatment. CBT=cognitive–behavioural therapy. SNRI=serotonin–norepinephrine reuptake inhibitor. SSRI=selective serotonin-reuptake inhibitor.
Figure 2 Network diagram representing direct comparisons among classes The width of lines represents the number of trials in which each direct comparison is made. The size of each circle represents the number of people who received each treatment. CBT=cognitive–behavioural therapy. SNRI=serotonin–norepinephrine reuptake inhibitor. SSRI=selective serotonin-reuptake inhibitor.CC BY · PubMed Central
Figure 3 Effect of each class of intervention compared with waitlist Data are standardised mean difference and 95% credible intervals compared with waitlist as a reference. CBT=cognitive–behavioural therapy. SNRI=serotonin–norepinephrine reuptake inhibitor. SSRI=selective serotonin-reuptake inhibitor.
Figure 3 Effect of each class of intervention compared with waitlist Data are standardised mean difference and 95% credible intervals compared with waitlist as a reference. CBT=cognitive–behavioural therapy. SNRI=serotonin–norepinephrine reuptake inhibitor. SSRI=selective serotonin-reuptake inhibitor.CC BY · PubMed Central
Figure 4 Efficacy of classes of interventions Classes of interventions are ordered according to efficacy ranking from largest mean effect (top, left) to smallest mean effect (bottom, right). Data in blue represent the effects on symptoms of social anxiety (SMD [95% CrI]); SMD less than 0 favours the intervention in the row. Data in green represent the effects on recovery (RR [95% CrI]); RR greater than 1 favours the intervention in the column. Significant results are shaded dark blue and dark green. CBT=cognitive–behavioural therapy. CrI=credible interval. EXER=promotion of exercise. EXPO=exposure and social skills. MAOI=monoamine oxidase inhibitors. NSSA=noradrenergic and specific serotonergic antidepressants. OTHER=other psychological therapy. PDPT=psychodynamic psychotherapy. PSYP=psychological placebo. RR=risk ratio. SHNS=self-help without support. SHWS=self-help with support. SMD=standardised mean difference. SNRI=serotonin–norepinephrine reuptake inhibitors. SSRI=selective serotonin-reuptake inhibitor.
Figure 4 Efficacy of classes of interventions Classes of interventions are ordered according to efficacy ranking from largest mean effect (top, left) to smallest mean effect (bottom, right). Data in blue represent the effects on symptoms of social anxiety (SMD [95% CrI]); SMD less than 0 favours the intervention in the row. Data in green represent the effects on recovery (RR [95% CrI]); RR greater than 1 favours the intervention in the column. Significant results are shaded dark blue and dark green. CBT=cognitive–behavioural therapy. CrI=credible interval. EXER=promotion of exercise. EXPO=exposure and social skills. MAOI=monoamine oxidase inhibitors. NSSA=noradrenergic and specific serotonergic antidepressants. OTHER=other psychological therapy. PDPT=psychodynamic psychotherapy. PSYP=psychological placebo. RR=risk ratio. SHNS=self-help without support. SHWS=self-help with support. SMD=standardised mean difference. SNRI=serotonin–norepinephrine reuptake inhibitors. SSRI=selective serotonin-reuptake inhibitor.CC BY · PubMed Central

Verification

Claims the paper makes

2 Valid · 1 Not valid · 8 Not checked · 78 Own results and interpretations

50 more claims

Create a free account to see all 89 claims and to verify the 12 references still open.

See all claims — free account
  • It may state two separate claims as one. 26
  • The quote only partly states this claim. 3
  • Probably not a substantial claim. 12

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 36 references

Cited by

See all 680

Metadata

Authors
Mayo-Wilson, E., Dias, S., Mavranezouli, I., Kew, K., Clark, D. M., Ades, A. E., & Pilling, S.
Affiliations
  • University of Bristol (GB)
  • University College London (GB)
  • University of London (GB)
  • University of Oxford (GB)
Venue
The Lancet Psychiatry
Publisher
Elsevier BV
Published
2014-10
Volume
1
Issue
5
Pages
368-376
ISSN
2215-0366 (ISSN-L)
OpenAlex
W2151428461
Cited by
680
References
36
Citations by year
2026: 41 · 2025: 50 · 2024: 61 · 2023: 65 · 2022: 97 · 2021: 84 · 2020: 58 · 2019: 49 · 2018: 62 · 2017: 44 · 2016: 45 · 2015: 23 · 2014: 1
FWCI
5.06
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Psychiatry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Bristol Research (University of Bristol) (submittedVersion)
Funders
Wellcome Trust (069777)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Assessments
  • Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
Keywords
social anxiety disorder, adults, pharmacological interventions, psychological intervention, cognitive behavioral therapy, group cognitive behavioral therapy, exposure therapy, social skills training, self-help, psychodynamic psychotherapy, monoamine oxidase inhibitors, benzodiazepines, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, antiepileptic drugs, treatment efficacy comparison

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. https://app.cochat.ai/papers/10.1016/s2215-0366(14)70329-3
The paper
Mayo-Wilson, E., Dias, S., Mavranezouli, I., Kew, K., Clark, D. M., Ades, A. E., & Pilling, S. (2014). Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(14)70329-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.